Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
the first dose was administered on June 28th 2024 and the 2nd dose on December 4th 2024.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 35-year-old female patient who received HBV (Engerix B) for prophylaxis. Previously administered products included Engerix B (Received 1st dose on 28 June 2024). On 04-DEC-2024, the patient received the 2nd dose of Engerix B. On 04-DEC-2024, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: the first dose was administered on June 28th 2024 and the 2nd dose on December 4th 2024.). The outcome of the drug dose administration interval too long was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 30-JAN-2025 The reporter reported that a patient that came to receive the 3 dose of Engerix B, the first dose was administered on 28 June 2024 and the 2nd dose on 4 December 2024 which led to drug dose administration interval too long. The reporter want to know when the 3rd dose should be administered.